EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Metabolic Function and Therapeutic Potential of CD147 for Hematological Malignancies: An Overview

Isabella Spinello, Catherine Labbaye, Ernestina Saulle iD

International Journal of Molecular Sciences · 23.08.2024 · 25 (17) · 9178

DOI: 10.3390/ijms25179178 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 23.08.2024. Verfasst von Isabella Spinello und 2 weiteren Autor:innen. Beteiligte Einrichtung: Istituto Superiore di Sanità, National Center for Drug Research and Evaluation, 00161 Rome, Italy. Hauptthemen laut MEDLINE: Basigin, Hematologic Neoplasms, Tumor Microenvironment. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Istituto Superiore di Sanità (Rome, Italy).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hematological malignancies refer to a heterogeneous group of neoplastic conditions of lymphoid and hematopoietic tissues classified in leukemias, Hodgkin and non-Hodgkin lymphomas and multiple myeloma, according to their presumed cell of origin, genetic abnormalities, and clinical features. Metabolic adaptation and immune escape, which influence various cellular functions, including the proliferation and survival of hematological malignant tumor cells, are major aspects of these malignancies that lead to therapeutic drug resistance. Targeting specific metabolic pathways is emerging as a novel therapeutic strategy in hematopoietic neoplasms, particularly in acute myeloid leukemia and multiple myeloma. In this context, CD147, also known as extracellular matrix metalloproteinase inducer (EMMPRIN) or Basigin, is one target candidate involved in reprograming metabolism in different cancer cells, including hematological malignant tumor cells. CD147 overexpression significantly contributes to the metabolic transformation of these cancer cells, by mediating signaling pathway, growth, metastasis and metabolic reprogramming, through its interaction, direct or not, with various membrane proteins related to metabolic regulation, including monocarboxylate transporters, integrins, P-glycoprotein, and glucose transporter 1. This review explores the metabolic functions of CD147 and its impact on the tumor microenvironment, influencing the progression and neoplastic transformation of leukemias, myeloma, and lymphomas. Furthermore, we highlight new opportunities for the development of targeted therapies against CD147, potentially improving the treatment of hematologic malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BasiginHematologic NeoplasmsTumor MicroenvironmentHumansAnimalsSignal Transduction

Stichwörter der Autor:innen

CD147hematological malignanciesmetabolism

Substanzen

BasiginBSG protein, human

Autor:innen und Institutionen

  • Istituto Superiore di Sanità, National Center for Drug Research and Evaluation, 00161 Rome, Italy.

ORCID-Profile: Ernestina Saulle

Förderung

  • Istituto Superiore di Sanità (Rome, Italy)

Zitieren

APA

Spinello, I., Labbaye, C., & Saulle, E. (2024). Metabolic Function and Therapeutic Potential of CD147 for Hematological Malignancies: An Overview. International Journal of Molecular Sciences, 25(17), 9178. https://doi.org/10.3390/ijms25179178

Vancouver

Spinello I, Labbaye C, Saulle E. Metabolic Function and Therapeutic Potential of CD147 for Hematological Malignancies: An Overview. International Journal of Molecular Sciences. 2024;25(17):9178. doi:10.3390/ijms25179178

BibTeX
@article{Spinello2024,
  author = {Spinello, Isabella and Labbaye, Catherine and Saulle, Ernestina},
  title = {Metabolic Function and Therapeutic Potential of CD147 for Hematological Malignancies: An Overview},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {17},
  pages = {9178},
  doi = {10.3390/ijms25179178}
}
Kostenlos starten →